Vertex and Glaxo start Phase III study in HIV

VRTX and partner Glaxo (GLX; LSE:GLXO) began two open-label Phase III studies of VX-175 ( GW433908), a prodrug of the companies' Agenerase amprenavir protease inhibitor to treat HIV infection/AIDS. Th...